Earnings call transcript: Cera Sanitaryware’s Q4 2026 shows recovery

Cera Sanitaryware reported Q4 FY2026 revenue growth of 11.4% YoY to INR 644 crore, led mainly by 12% volume growth, though EBITDA margin fell 310 bps to 15.2% due to higher brass costs and trade discounts. Management guided FY2027 revenue growth of 18%-20%, with sanitaryware up 12% and faucetware up 18%, and said margins should recover to 14%-15% as pricing actions flow through. The company also highlighted INR 853 crore of cash, a 5.97% post-earnings share-price gain, and continued investment in Senator and Polipluz brands.

Analysis

The market is starting to price CERA less like a cyclical building-materials supplier and more like a distribution-and-brand compounder with a short-term supply advantage. The key second-order effect is that elevated brass/gas volatility is not just a margin headwind; it also acts as a gatekeeper that weakens smaller outsourced competitors and should let organized players with inventory and sourcing control take share over the next 1-2 quarters. That dynamic is most visible in retail and tier-2/3 channels, where service reliability matters more than absolute price, and where CERA can monetize its balance-sheet strength before the market fully normalizes.

The margin story is better than the headline suggests because the company has already pushed through most of the price repair, while the remaining drag is increasingly a discount-management issue rather than a structural cost problem. That means EBITDA can re-rate faster than revenue if demand stays firm into Q1/Q2, since discount rollback is a cleaner lever than raw price hikes. The risk is timing: if brass stabilizes but retail momentum fades, the company could be left with elevated brand spend, still-weak trade discounts, and only partial operating leverage.

The contrarian angle is that consensus may be overestimating the speed of the FY27 growth inflection from new brands. Senator/Polipluz look more like option value than near-term earnings drivers; the visible P&L contribution likely lags the distribution buildout by several quarters, so the market may be paying today for FY28 economics too early. More importantly, the best near-term earnings surprise is probably not the new brands but the core franchise benefiting from Morbi disruption and a temporary sourcing gap that can persist through the monsoon cycle.

Key Decisions for Investors

• Long CERA on a 3-6 month horizon; prefer adding on any post-rally consolidation rather than chasing strength. Upside is driven by margin normalization and share capture, while downside is cushioned by cash and pricing power.
• Buy CERA call spreads for the next 2 quarters if implied volatility is reasonable; structure around the Q1/Q2 margin recovery window where discount rollback should show through before new-brand spend fully scales.
• Pair trade: long CERA / short an outsourced-heavy tile or sanitaryware peer exposed to Morbi supply disruptions. The spread should widen over 1-2 quarters if CERA’s internalization and inventory buffer translate into share gains.
• Avoid extrapolating the new-brand revenue run-rate into FY27 earnings; treat Senator/Polipluz as a FY28+ call option. If the stock rerates further on that narrative alone, take profits into strength.
• Monitor gross margin and discount commentary closely; if EBITDA margin fails to hold near 14-15% by Q1/Q2, cut exposure quickly because the market is currently pricing a cleaner recovery than the operating setup may deliver.